TransMedics Group, Inc. (NASDAQ:TMDX) Receives $122.70 Average Target Price from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $122.70.

Several analysts have commented on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Robert W. Baird cut their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, Piper Sandler cut their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NBC Securities Inc. purchased a new position in TransMedics Group in the 1st quarter valued at $25,000. GAMMA Investing LLC lifted its holdings in TransMedics Group by 43,744.2% in the 1st quarter. GAMMA Investing LLC now owns 105,226 shares of the company’s stock valued at $7,080,000 after purchasing an additional 104,986 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of TransMedics Group in the 4th quarter worth $4,131,000. Mackenzie Financial Corp increased its stake in shares of TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after acquiring an additional 349,403 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of TransMedics Group in the 4th quarter worth $1,436,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Up 11.0 %

NASDAQ:TMDX opened at $75.41 on Thursday. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a 50-day moving average of $70.62 and a 200 day moving average of $82.64. The firm has a market cap of $2.54 billion, a PE ratio of 80.22 and a beta of 2.14. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.